Olanzapine plus carbamazepine v.carbamazepine alone in treating manic episodes
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Background: Combinations of olanzapine and carbamazepine are often used in clinical practice in the management of mania. Aims: To assess the efficacy and safety of olanzapine plus carbamazepine in mixed and manic bipolar episodes. Method: Randomised, double-blind, 6-week trial of olanzapine (10–30 mg/day) plus carbamazepine (400–1200 mg/day;n=58)v.placebo plus carbamazepine (n=60) followed by open-label, 20-week olanzapine (10–30 mg/day) plus carbamazepine (400–1200 mg/day,n=86), with change in manic symptoms as main outcome measure. Safety and pharmacokinetics were also evaluated. Results: There were no significant differences (baseline to endpoint) in efficacy measures between treatment groups, but at 6 weeks triglyceride levels were significantly higher (P=0.008) and potentially clinically significant weight gain (⩾7%) occurred more frequently (24.6%v.3.4%,P=0.002) in the combined olanzapine and carbamazepine group. Carbamazepine reduced olanzapine concentrations but olanzapine had no effect on carbamazepine concentrations. Conclusions: The combination of olanzapine and carbamazepine did not have superior efficacy to carbamazepine alone. The increases in weight and triglycerides observed during combination treatment are a matter of concern.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bowden, C. L. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.5.481 · Cited by 678
Self-citationOlanzapine versus placebo in the treatment of acute mania
Tohen, M., Sanger, T. M., McElroy, S. L., Tollefson, G. D., Chengappa, K. N. R., Daniel, D. G., Petty, F., Centorrino, F., Wang, R., Grundy, S. L., et al. (1999) · American Journal of Psychiatry · doi:10.1176/ajp.156.5.702 · Cited by 585
Self-citationYatham, L. N., Grossman, F., Augustyns, I., Vieta, E., & Ravindran, A. (2003) · British Journal of Psychiatry · doi:10.1192/bjp.182.2.141 · Cited by 248
Cited by
Yatham, L. N., Kennedy, S. H., Parikh, S. V., Schaffer, A., Beaulieu, S., Alda, M., O’Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., et al. (2013) · Bipolar Disorders · doi:10.1111/bdi.12025 · Cited by 1,217
Yatham, L. N., Kennedy, S. H., Schaffer, A., Parikh, S. V., Beaulieu, S., O'Donovan, C., MacQueen, G., McIntyre, R. S., Sharma, V., Ravindran, A., et al. (2009) · Bipolar Disorders · doi:10.1111/j.1399-5618.2009.00672.x · Cited by 570
Grunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., & on behalf of the WFSBP Task Force on Treatment Guidelines for Bipolar Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.770551 · Cited by 421
Self-citationGrunze, H., Vieta, E., Goodwin, G. M., Bowden, C., Licht, R. W., Möller, H.-J., Kasper, S., WFSBP Task Force on Treatment Guide, Grunze, H., Vieta, E., et al. (2009) · The World Journal of Biological Psychiatry · doi:10.1080/15622970902823202 · Cited by 346
Self-citationCruz, N., Sanchez-Moreno, J., Torres, F., Goikolea, J. M., Valentí, M., & Vieta, E. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990344 · Cited by 121
Medications that cause weight gain and alternatives in Canada: a narrative review
Wharton, S., Raiber, L., Serodio, K., Lee, J., & Christensen, R. A. (2018) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s171365 · Cited by 100
Ogawa, Y., Tajika, A., Takeshima, N., Hayasaka, Y., & Furukawa, T. A. (2014) · CNS Drugs · doi:10.1007/s40263-014-0197-8 · Cited by 66
“Participants had already been treated with MSs before randomization in most studies in Comparison 1, although in one study [19] no patient was on MS before inclusion into the study and another study [26] set a washout phase.”
BackgroundMethodCombination Therapy for Manic Phases: A Critical Review of a Common Practice
Geoffroy, P. A., Etain, B., Henry, C., & Bellivier, F. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12017 · Cited by 47
“profiles; Table 3 provides an overview of RCT reporting safety and tolerability data for various combinations [21-25,29,30,34,41,42,44,45,48].”
Metadata
- Authors
- Tohen, M., Bowden, C. L., Smulevich, A. B., Bergstrom, R., Quinlan, T., Osuntokun, O., Wang, W. V., Oliff, H. S., Martenyi, F., Kryzhanovskaya, L. A., & Greil, W.
- Venue
- British Journal of Psychiatry
- Publisher
- Royal College of Psychiatrists
- Published
- 2008-02
- Volume
- 192
- Issue
- 2
- Pages
- 135-143
- ISSN
- 0007-1250 (ISSN-L)
- 1472-1465
- OpenAlex
- W2167488540
- Cited by
- 75
- References
- 3
- FWCI
- 7.31
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.